Publications

NEWS

14 Nov 2017

CONARIS sells filtration technology for stool transplantation

[more]

Forschung_und_Entwicklung_2016_web_en

2018

 

Kaiser K, Prystaz K, Vikman A, Haffner-Luntzer M, Bergdolt S, Strauss G, Waetzig GH, Rose-John S & Ignatius A (2018): Pharmacological inhibition of IL-6 trans-signaling improves compromised fracture healing after severe trauma. Naunyn Schmiedebergs Arch. Pharmacol. 391 (5): 523. (Abstract)

 

Baran P, Hansen S, Waetzig GH, Akbarzadeh M, Lamertz L, Huber HJ, Ahmadian MR, Moll JM & Scheller J (2018):
The balance of interleukin (IL-)6, IL-6·soluble IL-6 receptor (IL-6R) and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling. J. Biol. Chem. 293 (18): 6762. (Abstract)

 

Fangmann D, Theismann EM, Türk K, Schulte DM, Relling I, Hartmann K, Keppler JK, Knipp JR, Rehman A, Heinsen FA, Franke A, Lenk L, Freitag-Wolf S, Appel E, Gorb S, Brenner C, Seegert D, Waetzig GH, Rosenstiel P, Schreiber S, Schwarz K & Laudes M (2018): Targeted microbiome intervention by microencapsulated delayed-release niacin beneficially affects insulin sensitivity in humans. Diabetes Care 41 (3): 398. (Abstract)

 

Prystaz K, Kaiser K, Kovtun A, Haffner-Luntzer M, Fischer V, Rapp AE, Liedert A, Strauss G, Waetzig GH, Rose-John S & Ignatius A (2018): Distinct effects of interleukin-6 classic and trans-signaling in bone fracture healing. Am. J. Pathol. 188 (2): 474. (Abstract)

 

2017

 

Nikolaus S, Schulte B, Al-Massad N, Thieme F, Schulte DM, Bethge J, Rehman A, Tran F, Aden K, Häsler R, Moll N, Schütze G, Schwarz MJ, Waetzig GH, Rosenstiel P, Krawczak M, Szymczak S & Schreiber S (2017): Increased Tryptophan Metabolism is Associated With Activity of Inflammatory Bowel Diseases. Gastroenterology 153 (6): 1504. (Abstract)

 

Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, Cassidy L, Tholey A, Fickenscher H, Seegert D, Rosenstiel P & Schreiber S (2017): Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection.Gastroenterology 152 (4): 799. (Abstract)

 

2016

 

Aden K, Breuer A, Rehman A, Geese H, Tran F, Sommer J, Waetzig GH, Reinheimer TM, Schreiber S, Rose-John S, Scheller J & Rosenstiel P (2016): Classic IL-6R signalling is dispensable for intestinal epithelial proliferation and repair. Oncogenesis 5 (11): e270. (Abstract)

 

Wolf J, Waetzig GH, Chalaris A, Reinheimer TM, Wege H, Rose-John S & Garbers C (2016): Different soluble forms of the interleukin-6 family signal transducer gp130 fine-tune the blockade of interleukin-6 trans-signaling. J. Biol. Chem. 291 (31): 16186. (Abstract)

 

Lokau J, Nitz R, Agthe M, Monhasery N, Aparicio-Siegmund S, Schumacher N, Wolf J, Möller-Hackbarth K, Waetzig GH, Grötzinger J, Müller-Newen G, Rose-John S, Scheller J & Garbers C (2016): Proteolytic cleavage governs interleukin-11 trans-signaling. Cell Rep. 14: 1761. (Abstract)

 

Wolf J, Waetzig GH, Reinheimer TM, Scheller J, Rose-John S & Garbers C (2016): A soluble form of the interleukin-6 family signal transducer gp130 is dimerized via a C-terminal disulfide bridge resulting from alternative mRNA splicing. Biochem. Biophys. Res. Commun. 470: 870. (Abstract)

 

2015

 

Holmer R, Wätzig GH, Tiwari S, Rose-John S & Kalthoff H (2015): Interleukin-6 trans-signaling increases the expression of carcinoembryonic antigen-related cell adhesion molecules 5 and 6 in colorectal cancer cells. BMC Cancer 15: 975. (Abstract)

 

Mittelberger F, Meyer C, Waetzig GH, Zacharias M, Valentini E, Svergun DI, Berg K, Lorenzen I, Grötzinger J, Rose-John S & Hahn U (2015): RAID3 – An interleukin-6 receptor-binding aptamer with post-selective modification-resistant affinity. RNA Biol. 12 (9): 1043. (Abstract)

 

Goumas FA, Holmer R, Egberts JH, Gontarewicz A, Heneweer C, Geisen U, Hauser C, Mende M, Legler K, Roecken C, Becker T, Waetzig GH, Rose-John S & Kalthoff H (2015): Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. Int. J. Cancer 137 (5): 1035. (Abstract)

 

2014

 

Holmer R, Goumas FA, Waetzig GH, Rose-John S & Kalthoff H (2014): Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Hepatobiliary Pancreat. Dis. Int., 13 (4): 371. (Abstract)

 

Sommer J, Garbers C, Wolf J, Trad A, Moll JM, Sack M, Fischer R, Grötzinger J, Waetzig GH, Floss DM & Scheller J (2014): Alternative intronic polyadenylation generates the interleukin-6 trans-signaling inhibitor sgp130-E10. J. Biol. Chem., 289 (32): 22140. (Abstract)

 

Düsterhöft S, Höbel K, Oldefest M, Lokau J, Waetzig GH, Chalaris A, Garbers C, Scheller J, Rose-John S, Lorenzen I, Grötzinger J (2014): A disintegrin and metalloprotease 17 dynamic interaction sequence, the sweet tooth for the human interleukin-6 receptor. J. Biol. Chem. 289 (23): 16336. (Abstract)

 

2013

 

Garbers C, Spudy B, Aparicio-Siegmund S, Waetzig GH, Sommer J, Hölscher C, Rose-John S, Grötzinger J, Lorenzen I & Scheller J (2013): An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer. J. Biol. Chem. 288 (6): 4346. (Abstract)

 

2012

 

Spudy B, Sönnichsen FD, Waetzig GH, Grötzinger J & Jung S (2012): Identification of structural traits that increase the antimicrobial activity of a chimeric peptide of human β-defensins 2 and 3. Biochem. Biophys. Res. Commun. 427: 207. (Abstract)

 

Sommer J, Effenberger T, Volpi E, Waetzig GH, Bernhardt M, Suthaus J, Garbers C, Rose-John S, Floss DM & Scheller J (2012): Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes Interleukin-11 signaling. J. Biol. Chem. 287 (17): 13743. (Abstract)

 

Sodenkamp J, Waetzig GH, Scheller J, Seegert D, Grötzinger J, Rose-John S, Ehlers S & Hölscher C (2012): Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis. Immunobiology 217 (10): 996. (Abstract)

 

Waetzig GH & Rose-John S (2012): Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opin. Ther. Targets 16 (2): 225. (Abstract)

 

Schuett H, Oestreich R, Waetzig GH, Annema W, Luchtefeld M, Hillmer A, Bavendiek U, von Felden J, Divchev D, Kempf T, Wollert KC, Seegert D, Rose-John S, Tietge UJ, Schieffer B & Grote K (2012): Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 32 (2): 281. (Abstract)

 

2011

 

Garbers C, Thaiss W, Jones GW, Waetzig GH, Lorenzen I, Guilhot F, Lissilaa R, Ferlin WG, Grötzinger J, Jones SA, Rose-John S & Scheller J (2011): Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J. Biol. Chem. 286 (50): 42959. (Abstract)

 

Lorenzen I, Shang W, Perbandt M, Petoukhov MV, Svergun DI, Waetzig GH, Rose-John S, Hilgenfeld R and Grötzinger J (2011): The structure of the unliganded extracellular domain of the interleukin-6 signal transducer gp130 in solution. Eur. J. Cell Biol. 90(6-7): 515. (Abstract)

 

Barkhausen T, Tschernig T, Rosenstiel P, van Griensven M, Vonberg RP, Dorsch M, Mueller-Heine A, Chalaris A, Scheller J, Rose-John S, Seegert D, Krettek C, Waetzig GH (2011): Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit. Care Med. 39(6): 1407. (Abstract)

 

Malchow S, Thaiss W, Jänner N, Waetzig GH, Gewiese-Rabsch J, Garbers C, Yamamoto K, Rose-John S & Scheller J (2011): Essential role of neutrophil mobilization in concanavalin A-induced hepatitis is based on classic IL-6 signaling but not on IL-6 trans-signaling. Biochim. Biophys. Acta – Mol. Basis Dis. 1812: 290. (Abstract)

 

Billmann-Born S, Till A, Arlt A, Lipinski S, Sina C, Latiano A, Annese V, Häsler R, Kerick M, Manke T, Seegert D, Hanidu A, Schäfer H, van Heel D, Li J, Schreiber S & Rosenstiel P (2011). Genome-Wide Expression Profiling Identifies an Impairment of Negative Feedback Signals in the Crohn's Disease-Associated NOD2 Variant L1007fsinsC. J. Immunol. 186: 4027. (Abstract)

 

2010

 

Waetzig GH, Chalaris A, Rosenstiel P, Suthaus J, Holland C, Karl N, Vallés Uriarte L, Till A, Scheller J, Grötzinger J,  Schreiber S, Rose-John S, and Seegert D (2010): N-linked glycosylation is essential for the stability, but not the signaling function of the interleukin-6 signal transducer gp130. J. Biol. Chem. 285(3): 1781.(Abstract)

 

2009

 

Wilms H, Rosenstiel P, Romero-Ramos M, Arlt A, Schafer H, Seegert D, Kahle PJ, Odoy S, Claasen JH, Holzknecht C, Brandenburg LO, Deuschl G, Schreiber S, Kirik D, Lucius R (2009): Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils. Int. J. Immunopathol. Pharmacol. 22(4): 897

 

Derer S, Waetzig GH, Seegert D, Nikolaus S, Schreiber S, Rosenstiel P (2009): A possible link between TIMP-1 induction and response to infliximab. Gut 58(6): 888.

 

2008

 

Tenhumberg S, Waetzig GH, Chalaris A, Rabe B, Seegert D, Scheller J, Rose-John S, Grötzinger S (2008):  Structure guided optimization of the interleukin-6 transsignaling antagonist sgp130. J. Biol. Chem. 283(40): 27200.

 

Till A, Rosenstiel P, Bräutigam K, Sina C, Jacobs G, Oberg HH, Seegert D, Chakraborty T, Schreiber S (2008): A role for membrane-bound CD147 in NOD2-mediated recognition of bacterial cytoinvasion. J. Cell Sci. 121: 487.

 

2007

 

Rabe B, Chalaris A, May U, Waetzig GH, Seegert D, Williams AS, Jones SA, Rose-John S, Scheller J (2007): Transgenic blockade of Interleukin-6-trans-signaling abrogates inflammation. Blood 111: 1021.

 

Rose-John S, Waetzig GH, Scheller J, Grötzinger J, Seegert D (2007): The IL-6/sIL-6R complex as novel target for therapeutic approaches. Expert Opin. Ther. Targets 11: 613.

 

2006

 

Rosenstiel P, Huse K, Till A, Hampe J, Braeutigam K, Nikolaus S, Sina C, Waetzig GH, Platzer M, Seegert D, Schreiber S (2006): A short splice form of NOD2 (NOD2-S) is an endogenous inhibitor of NOD2/RIP-induced signaling pathways. Proc. Natl. Acad. Sci. U.S.A. 103: 3280.

 

Weichart D, Gobom J, Klopfleisch S, Hasler R, Gustavsson N, Billmann S, Lehrach H, Seegert D, Schreiber S, Rosenstiel P (2006): Analysis of NOD2-mediated proteome response to muramyl-dipeptide in HEK293 cells. J. Biol. Chem. 281: 2380.

 

2005

 

Costello CM, Mah N, Häsler R, Rosenstiel P, Waetzig GH, Hahn A, Lu T,Gurbuz Y, Nikolaus S, Albrecht M, Hampe J, Lucius R, Klöppel G, Eickhoff H, Lehrach H, Lengauer T, Schreiber S (2005): Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med. 2: 771.

 

Valentonyte R, Hampe J, Huse K, Rosenstiel P, Albrecht M, Stenzel A, Nagy M, Gaede KI, Franke A, Haesler R, Koch A, Lengauer T, Seegert D, Reiling N, Ehlers S, Schwinger E, Platzer M, Krawczak M, Müller-Quernheim J, Schürmann M,  Schreiber S (2005): “Sarcoidosis is associated with a truncating splice site mutation in BTNL2”. Nat. Genet. 37: 357.

 

Till A, Rosenstiel P, Krippner-Heidenreich A, Mascheretti-Croucher S, Croucher PJP, Schafer H, Scheurich P, Seegert D,  Schreiber S (2005): The Met-196 -> Arg Variation of Human Tumor Necrosis Factor Receptor 2 (TNFR2) Affects TNF-{alpha}-induced Apoptosis by Impaired NF-kB Signaling and Target Gene Expression. J. Biol. Chem. 280: 5994.

 

Rosenstiel P, Agnholt J, Kelsen J, Medici V, Waetzig GH, Seegert D, Schreiber S (2005): Differential modulation of p38 mitogen-activated protein kinase and STAT3 signaling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn’s disease. Gut 54:314.

 

2004

 

Waetzig GH, Rosenstiel P, Arlt A, Till A, Bräutigam K, Schäfer H, Rose-John S, Seegert D, Schreiber S (2004): Soluble tumor necrosis factor (TNF) receptor-1 induces monocyte apoptosis via reverse TNF signaling and autocrine transforming growth factor-beta1. FASEB J., doi:10.1096/fj.04-2073fje. Printed summary (2005): FASEB J. 19:91.

 

La Ferla K, Seegert D, Schreiber S (2004): Activation of NF-kappaB in intestinal epithelial cells by E. coli strains isolated from the colonic mucosa of IBD patients. Int. J. Colorectal Dis. 19: 334.

 

Stoll M, Corneliussen B, Costello CM, Waetzig GH, Mellgard B, Koch WA, Rosenstiel P, Albrecht M, Croucher PJP, Seegert D, Nikolaus S, Hampe J, Lengauer T, Pierrou S, Foelsch UR, Mathew CG, Lagerstrom-Fermer M, Schreiber S (2004): Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat. Genet. 36: 476.

 

Kahlke V, Schafmayer C, Schniewind B, Seegert D, Schreiber S, Schröder J (2004): Are postoperative complications genetically determined by TNF-beta NcoI gene polymorphism? Surgery 135: 365.

 

Waetzig GH, Schreiber S (2004): Mechanisms of infliximab: the reverse side of a drug effect. Inflamm. Bowel Dis. 10, Suppl. 1: S38. (Review)

 

2003

 

Waetzig GH, Rosenstiel P, Nikolaus S, Seegert D, Schreiber S (2003): Differential p38 mitogen-activated protein kinase target phosphorylation in responders and non-responders to infliximab. Gastroenterology 125: 633.

 

Waetzig GH, Schreiber S (2003): Mitogen-activated protein kinases in chronic intestinal inflammation: targeting ancient pathways to treat modern diseases. Aliment. Pharmacol. Ther. 18: 17. (Review)

 

Rosenstiel P, Fantini M, Bräutigam K, Kühbacher T, Waetzig GH, Seegert D, Schreiber S (2003): TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 124: 1001.

 

2002

 

Schreiber S, Rosenstiel P, Hampe J, Nikolaus S, Groessner B, Schottelius A, Kühbacher T, Hämling J, Fölsch UR, Seegert D (2002): Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 51: 379.

 

Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S (2002): p38 mitogen-activated protein kinase is activated and linked to TNF- signaling in inflammatory bowel disease. J. Immunol. 168: 5342.

 

Seegert D, Schreiber S (2002): Overview: interleukin-16 and its role in inflammatory bowel disease. Curr. Opin.  Investig. Drugs 3: 562. (Review)

 

2001

 

Seegert D, Rosenstiel P, Pfahler H, Pfefferkorn P, Nikolaus S, Schreiber S (2001): Increased expression of IL-16 in inflammatory bowel disease. Gut 48: 326.

Deutsch

 

 

© 2002-2018 Conaris Research Institute AG  I  Impressum I Data Privacy Statement I Disclaimer I Terms of Business